Windsor Bux

?? Happy Thanksgiving from all of us at Windsor Bux! ?? As we celebrate this season of gratitude, we want to take a moment to thank our incredible team, valued clients, and partners. Your support and hard work are what drive our success, and we are truly appreciative. May your holiday be filled with joy, warmth, and delightful moments with loved ones. We look forward to an exciting year ahead, filled with new opportunities and collaborations. Wishing everyone a happy and peaceful Thanksgiving! ????

?? Sarepta Agrees Licensing Agreement with Arrowhead! ?? Sarepta Therapeutics has announced a major deal with Arrowhead Pharmaceuticals, investing $500M in cash and an additional $325M in equity to secure worldwide licensing rights to seven programs. This includes four clinical and three preclinical programs, as well as a discovery partnership focused on six targets. The deal highlights the growing potential of RNA interference (RNAi) therapies, as Sarepta will gain exclusive rights to innovative programs like: ??ARO-DUX4: A promising treatment for facioscapulohumeral muscular dystrophy (FSHD) ??ARO-DM1: Targeting myotonic dystrophy type 1 (DM1) ??ARO-MMP7: Addressing idiopathic pulmonary fibrosis (IPF) ??ARO-ATXN2: A therapy for spinocerebellar ataxia 2 (SCA2) This partnership positions both companies at the forefront of cutting-edge genetic medicine, with Sarepta poised to advance these programs into clinical trials, bringing hope to patients with serious, rare diseases. After Roche's recent acquisition of Poseida Therapeutics, Inc., Cell and Gene Therapies seem to be making a resurgence. With Obesity/ Metabolic therapies a massive investment area for 2024, do you think 2025 is the year for Cell and Gene Therapies? #Biotech #RNAi #Partnerships #Innovation #GeneticTherapies #Sarepta #ArrowheadPharmaceuticals #FSHD #DM1 #IPF #SCA2

Roche buys out CAR-T partner Poseida Therapeutics, Inc. for $1B upfront https://lnkd.in/dS9-y2vG

Pharma/Biotech Roundup ?? Novartis: Has acquired Kate Therapeutics for up to $1.1 Billion to further enhance and strengthen their ongoing efforts to advance gene therapeutics for patients. Enveda: Announced an oversubscribed $130 Million Series C funding to deliver multiple clinical readouts from a pipeline of 10 development candidates. Donald Trump has elected John Hopkins researcher Martin Makary to lead FDA. Ratio Therapeutics: Enters license and collaboration agreement with Novartis for SSTR2-targeting Radiotherapeutic candidate. Ratio will receive up to $745 Million. Kura Oncology, Inc.: Announces global strategic collaboration with Kyowa Kirin Co., Ltd. to develop and commercialize Ziftomenib in acute leukemias. Kura to receive a $330 Million upfront payment and up to $1.2 Billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors. Valora Therapeutics, Inc.: Therapeutics: Raises $30 Million seed financing to transform immunotherapy with novel glyco-immune checkpoint platform. Venrock: Has added $500 Million to its healthcare investing strategy. Aclaris Therapeutics, Inc.: Announces exclusive, global license agreement with Biosion, adding potential best-in-class biologics to pipeline. Biosion will receive over $40 Million upfront, and up to $900 Million in milestones. Halozyme, Inc.: Withdraws $2.1 Billion proposal to acquire Evotec following Evotecs unwillingness to engage in discussions. Amgen: Names Stanford geneticist and biotech co-founder Howard Chang as new Chief Scientific Officer. Sage Therapeutics: Set to discontinue the development of neurological disorder drug Dalzanemdor after failing trial in Huntington's disease. Lexicon Pharmaceuticals, Inc.: To lay off?60% of workforce after the FDA noted deficiencies in its application seeking approval for its diabetes drug.

??Frazier Raises $2.3bn Fund Following Industry Momentum ?? Frazier Healthcare Partners has successfully closed its Growth Buyout Fund XI at $2.3 billion, reaching its hard cap in just 6 months! This growth fund will focus on controlling stakes in middle-market healthcare companies. This follows the firm’s recent success with Frazier Life Sciences, which raised $630 million for its evergreen Public Fund. The latest fund attracted diverse global investors, including sovereign wealth funds and public pension funds, with New Mexico State Investment Council committing $150M. With over 30 years of industry expertise, Frazier’s strategic focus on emerging trends and top executive talent continues to resonate with investors. Since its founding in 1991, the firm has raised $9B+ and invested in 200+ companies. #PrivateEquity #HealthcareInvesting #GrowthCapital #FrazierHealthcare #InvestorConfidence #HealthcareInnovation

Novartis seeks more bolt-on deals as it purchases neuro startup for up to $1.1B https://lnkd.in/dpCd_jXB

?? Jupiter Bioventures Raises $70 Million to Launch Biotech Start-ups Targeting Cancer and Related Diseases ?? Founding investors Mission BioCapital and Mayo Clinic, joined by leading Life Science investors to support the creation of eight to ten biotech companies developing therapies for cancer and other diseases where cancer biology provides insights. Founded by biotech entrepreneurs Nathaniel David, PhD, and Norman Sharpless, Jupiter follows a “science-first” model to minimize risk and maximize returns. The company identifies high-potential projects, or “Moons,” and validates their scientific basis before spinning them into independent companies. The current moons include: ?? Ganymede: Targeting NRF2-dependent cancers ?? Persistence: Better, faster, and much cheaper CAR T therapies ?? Artemis: Targeting cancers with altered cohesin complex function ?? Artemis: Engineering targeted growth factors Which moon are you most excited by? #Biotech #Innovation #Healthcare #VentureCapital #CancerResearch #LifeSciences #Entrepreneurship #Pharma

Novartis, Ratio sign radiopharmaceutical pact to the tune of $745M biobucks https://lnkd.in/dvbVEqrc

Eisai US terminates Phase 3 trial of Dravet drug, citing recruitment challenges https://lnkd.in/d2_27nfw